European recommendations for the clinical use of HIV drug resistance testing: 2011 update

Andrea De Luca, A Vandamme, Rj Camacho, F Ceccherini Silberstein, L Palmisano, D Paraskevis, R Paredes, M Poljak, J Schmit, V Soriano, H Walter, A. Sönnerborg

Risultato della ricerca: Contributo in rivistaArticolo in rivista

116 Citazioni (Scopus)

Abstract

The European HIV Drug Resistance Guidelines Panel, established to make recommendations to clinicians and virologists, felt that sufficient new information has become available to warrant an update of its recommendations, explained in both pocket guidelines and this full paper. The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure. The Panel recommends genotyping in most situations, using updated and clinically evaluated interpretation systems. It is mandatory that laboratories performing HIV resistance tests take part regularly in external quality assurance programs, and that they consider storing samples in situations where resistance testing cannot be performed as recommended. Similarly, it is necessary that HIV clinicians and virologists take part in continuous education and discuss problematic clinical cases. Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response.
Lingua originaleEnglish
pagine (da-a)77-108
Numero di pagine32
RivistaAIDS Reviews
Volume13
Stato di pubblicazionePubblicato - 2011

Keywords

  • Anti-HIV Agents
  • Drug Resistance, Viral
  • Europe
  • Genotype
  • HIV Infections
  • HIV-1
  • Humans
  • Microbial Sensitivity Tests
  • Phenotype
  • Practice Guidelines as Topic

Fingerprint

Entra nei temi di ricerca di 'European recommendations for the clinical use of HIV drug resistance testing: 2011 update'. Insieme formano una fingerprint unica.

Cita questo